Welcome to Pangaea insights

Our collective intelligence provides an unrivalled breadth and depth of knowledge.

Pangaea’s ongoing relationships with key industry stakeholders facilitate continuous updates and dissemination of relevant market intelligence. Check back often for new posts!

Pangaea Express: Supreme Court of Canada Dismisses Appeal in SOLIRIS case

March 28, 2022
On March 24, 2022, the Supreme Court of Canada dismissed the application by the Attorney General of Canada in its appeal to the Federal Court Decision in the SOLIRIS case.

Pangaea Express: Quebec Court of Appeal Case

February 25, 2022
The Quebec Court of Appeal has confirmed that is it unconstitutional for the PMPRB to compel companies to provide information from 3rd party agreements.

Pangaea Express: Delay until July 1, 2022 for Patented Medicines Regulations

December 24, 2021
On December 23, 2021, the Minister of Health, Jean-Yves Duclos announced a delay in the coming-into-force of the Regulations Amending the Patented Medicines Regulations by six months.

Pangaea Express: PMPRB Not Moving Forward July 15 with Proposed Changes

December 20, 2021
On December 17, 2021, the PMPRB posted an update that read, “The Board has decided not to proceed with the changes that were proposed in the July 15, 2021 Notice and Comment.

Pangaea Express: What to Make of the Latest Announcements re: PMPRB?

August 5, 2021
Read about the two major announcements have been made in the last couple of weeks pertaining to the PMPRB.

Pangaea Express: Establishment of Advisory Panel to Design Pan-Canadian Formulary

July 28, 2021
CADTH has announced the establishment of a Special Advisory Panel to design a potential pan-Canadian formulary.

Pangaea Express: PMPRB Third Delay

June 28, 2021
The PMPRB has updated their website to state the coming-into-force of the amended Patented Medicines Regulations has been further delayed until January 1, 2022.

Pangaea Express: Uncovering PMPRB's "Mythbusting" Campaign Against Patient Groups

May 28, 2021
Twitter was abuzz with a letter from Christopher MacLeod, Canadian Cystic Fibrosis Treatment Society to the President of the Treasury Board, House of Commons & the Auditor General Canada with a request to investigate PMPRB for “targeting & de-legitimizing the Patient Voice”.

Pangaea Express: Quebec Announces Biosimilars Switch Strategy

May 19, 2021
Quebec will be moving to a biosimilars only program by April 12, 2022.

COVID-19 Sparks Transformation of the Pharma Model

May 5, 2021
COVID-19 is a humanitarian crisis that’s now having a growing impact on Canadian healthcare. Popular opinion seems to be that “the new normal”, whatever that looks like, will not arrive before the second half of 2021.
← Prev
Page 2 of 10
Next →